Format

Send to

Choose Destination
Swiss Med Wkly. 2015 May 29;145:w14139. doi: 10.4414/smw.2015.14139. eCollection 2015.

Idiopathic pulmonary fibrosis: the turning point is now!

Author information

1
Department of Pulmonary Medicine, Inselspital, University Hospital Berne, Switzerland.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival. Recent studies have improved understanding of IPF and new discoveries have led to novel treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical clinical findings and elaborate diagnostic procedures according to current guidelines and our daily practice approach. The role of biomarkers will briefly be outlined. Finally, we discuss novel antifibrotic treatment options for IPF (pirfenidone, nintedanib) and the management of patients regarding to comorbidities and complications. Both pirfenidone and nintedanib were shown to reduce the progression of IPF and therefore represent novel therapeutic strategies in this so far untreatable chronic lung disease.

PMID:
26024356
DOI:
10.4414/smw.2015.14139
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for EMH Swiss Medical Publishers Ltd.
Loading ...
Support Center